About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Risk Identification of Long-term Complications | Clinical Trials | Clareo Health

Back to clinical trial search

Enrolling By InvitationNCT06235866

Risk Identification of Long-term Complications

The investigators retrospectively analyze the clinical characteristics of severe COVID-19 in our hospital, and then establish a prediction model for long-term complications in patients with severe COV...

Lead sponsor: Wuhan Central Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Wuhan Central Hospital

At present, there is a lack of prediction models for the long-term complications of severe COVID-19. Therefore, the investigators used the hospital big data platform to retrospectively analyze the clinical characteristics of severe COVID-19 in our hospital, and conducted cohort follow-up of the changes in lung function including FEV1, FVC，FEV1% and DLCO, etc and and high-resolution CT of patients after discharge. COX model and other statistical methods were used to establish a prediction model for long-term complications of severe COVID-19, and early identification and intervention, strengthen follow-up, and improve the prognosis of patients.

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•The patient met the diagnostic criteria for severe COVID-19

Exclusion Criteria

•Pregnant women Patients who died of COVID-19 Patients younger than 18 years of age without pulmonary CT

Related studies

TERMINATEDPhase 3

Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

NCT05254990 · Infectious Pneumonia, Severe COVID-19

Managed Access Programs for INC424, Ruxolitinib

NCT04745637 · Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), and more

COMPLETEDPhase 3

Effect of Traditional Chinese Medicine of Severe COVID-19

NCT06714032 · Severe COVID-19

WITHDRAWNPhase 2/3

An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY

NCT04575064 · SARS-CoV-2 Infection, COVID-19, and more

Corticosteroids in Severe COVID-19 (ASAP-ESICM/ESAIC Study)

NCT04866082 · Severe COVID-19

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 8, 2024Terms

Trial snapshot

StatusENROLLING_BY_INVITATION

Phase—

Enrollment500

Start dateFeb 2023

Last updatedMay 8, 2024

Condition

Severe COVID-19

Locations shown

Follow-up of patients with severe COVID-19

Wuhan

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 8, 2024Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions